IP Library Granted Patent US 8,513,008
Granted Patent B2
US 8,513,008 · App. 11/400,774 · Granted Aug 20, 2013

Mature dendritic cell compositions and methods for culturing same

Inventors: Irina Tcherepanova (Rougemont, NC); Melissa Adams (Chapel Hill, NC)
Assignee: Argos Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,513,008
App. No.
11/400,774
Granted
Aug 20, 2013
Kind
B2
Abstract

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-γR) agonist and/or a tumor necrosis factor alpha receptor (TNF-αR) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7 + mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.

Claims (2)

1. An isolated dendritic cell comprising a CD40L polypeptide consisting of amino acid residues 21-261 of SEQ ID NO:2.

2. A dendritic cell comprising a CD40L polypeptide consisting of amino acid residues 21-261 of SEQ ID NO:2, wherein said cell comprises an in vitro-transcribed RNA encoding said CD40L polypeptide.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2010
From: KYOWA HAKKO KIRIN CO., LTD.
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 024753/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2010
From: KIRIN HOLDINGS KABUSHIKI KAISHA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 024534/0045 →
CHANGE OF NAME Recorded Jun 14, 2010
From: KAISHA, KIRIN BEER KABUSHI
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 024534/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2006
From: HEALY, DONALD, PH.D.; TCHEREPANOVA, IRINA; ADAMS, MELISSA; HINOHARA, ATSUSHI; DEBENEDETTE, MARK
To: ARGOS THERAPEUTICS, INC.; KIRIN BEER KABUSHIKI KAISHA
Reel/Frame 018046/0521 →
Continuity (4)
Continuation In Part 11246387 · Oct 7, 2005
Continuation In Part PCTUS2005036304 · Oct 7, 2005
Provisional Application 60522512 · Oct 7, 2004
Related Publication 20070082400A1 · Apr 12, 2007